Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine
by Piero Colombatto
1, Barbara Coco
1 [ORCID] , Ferruccio Bonino
2 [ORCID] and Maurizia R. Brunetto
1,2,3,* [ORCID]
1
Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, Department of Medical Specialties, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy
2
Institute of Biostructure and Bioimaging, National Research Council, Via De Amicis 95, 80145 Naples, Italy
3
Internal Medicine, Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, 56127 Pisa, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Pietro Andreone and Stefano Brillanti
Viruses 2022, 14(4), 701; https://doi.org/10.3390/v14040701
Received: 13 February 2022 / Revised: 22 March 2022 / Accepted: 23 March 2022 / Published: 28 March 2022
(This article belongs to the Special Issue Viral Hepatitis Treatment)
View Full-Text Download PDF Browse Figures
Citation Export
Abstract
The currently available antiviral treatments (Peg-Interferon-α and Nucleos(t)ide Analogues, NA) for chronic hepatitis B (CHB) achieve a functional cure (serum HBsAg and HDV-DNA clearance) of HBV infection in a limited number of patients. Nevertheless, the continuous pharmacological suppression of viral replication by NA halts liver disease progression lowering the risk of HCC development and improving the survival. In the near future, to fully exploit the potential of old and new drugs for HBV treatment a personalized approach to the patients will be required according to an accurate definition of their virologic, immunologic and clinical profile. View Full-Text
Keywords: HBV; chronic hepatitis B; Interferon-α; nucleos(t)ide analogues; antiviral treatment; HBV functional cure 作者: StephenW 时间: 2022-4-23 20:33